Crystagen
/ Khavinson-tradition tripeptide (Glu-Asp-Pro); proposed immune bioregulatorALIAS · EDP · Glu-Asp-Pro · Immune peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Crystagen appears in indexed Russian-language gerontology literature within Khavinson-group panels of immunoprotective short peptides (e.g. Chervyakova 2014, Adv Gerontol). No Western Phase 1 or later trials.
Crystagen is a synthetic tripeptide of the Khavinson sequence-specific bioregulator class proposed to act on cells of the immune system. Chervyakova 2014 reported in spleen-aging cell models that crystagen, alongside vilon, thymogen, and an R-1 peptide, exhibits B-cell-activating effects; the same paper noted that, unlike the other peptides tested, crystagen did not drive cellular renewal in aging spleen. The class-level mechanistic hypothesis is sequence-specific DNA binding and transcriptional modulation; crystagen-specific molecular target assignment has not been definitively established.
Tier 4. Indexed primary evidence is Russian-language cell-culture and aging-tissue data from the Khavinson group (Chervyakova 2014). No Phase 1 or later human trials are indexed.
No formal human safety database. No peptide-specific safety record beyond inclusion in Khavinson-group cell-culture panels.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature (Khavinson group, Saint-Petersburg Institute of Bioregulation and Gerontology) without independent Western replication. Even within the Khavinson corpus, the Chervyakova 2014 report describes crystagen as B-cell-activating but specifically not driving cellular renewal in aging spleen — a more modest signal than vendor marketing claims of immune-system regeneration. Vendor-sold material in the US research-chemical channel cannot be cross-checked against any pharmaceutical reference standard.